key: cord-0691965-8r8z8am1
authors: Paparoupa, Maria; Aldemyati, Razaz; Roggenkamp, Hannes; Berinson, Benjamin; Nörz, Dominik; Olearo, Flaminia; Kluge, Stefan; Roedl, Kevin; de Heer, Geraldine; Wichmann, Dominic
title: The prevalence of early‐ and late‐onset bacterial, viral, and fungal respiratory superinfections in invasively ventilated COVID‐19 patients
date: 2022-01-04
journal: J Med Virol
DOI: 10.1002/jmv.27548
sha: ae2db9e989e1b262008abd6ceece8bd679e4b747
doc_id: 691965
cord_uid: 8r8z8am1

The role of respiratory superinfections in patients with coronavirus disease 2019 (COVID‐19) pneumonia remains unclear. We investigated the prevalence of early‐ and late‐onset superinfections in invasively ventilated patients with COVID‐19 pneumonia admitted to our department of intensive care medicine between March 2020 and November 2020. Of the 102 cases, 74 (72.5%) received invasive ventilation and were tested for viral, bacterial, and fungal pathogens on Days 0–7, 8–14, and 15–21 after the initiation of mechanical ventilation. Approximately 45% developed one or more respiratory superinfections. There was a clear correlation between the duration of invasive ventilation and the prevalence of coinfecting pathogens. Male patients with obesity and those suffering from chronic obstructive pulmonary disease and/or diabetes mellitus had a significantly higher probability to develop a respiratory superinfection. The prevalence of viral coinfections was high, with a predominance of the herpes simplex virus (HSV), followed by cytomegalovirus. No respiratory viruses or intracellular bacteria were detected in our cohort. We observed a high coincidence between Aspergillus fumigatus and HSV infection. Gram‐negative bacteria were the most frequent pathogen group. Klebsiella aerogenes was detected early after intubation, while Klebsiella pneumoniae and Pseudomonas aeruginosa were related to a prolonged respiratory weaning.

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel β-coronavirus, identified to consist the main pathogenic agent of coronavirus disease 2019 (COVID- 19) , an ongoing pandemic, challenging the public health system worldwide. SARS-CoV-2 primarily affects the respiratory system and causes viral pneumonia, which can lead to the development of acute respiratory distress syndrome (ARDS). The involvement of extrapulmonary organs, during the course of the disease, has been also described in the literature. [1] [2] [3] Beyond the pathogenesis of SARS-CoV-2, respiratory coexisting infections with viruses, bacteria, and fungi have been reported, but their role in diagnosis, clinical presentation, and prognosis of the disease remains unclear. 4 Preliminary evidence shows that microbial copathogens may increase the morbidity and mortality of COVID-19, especially in critically ill patients. Thus, the difficulty to adjudicate in the presence of a respiratory superinfection, the clinical relevance of the identified microorganisms, and the antimicrobial treatment remains challenging.

Clinical deterioration, elevated inflammatory markers, and bilateral radiological infiltrates may lead to a misperception regarding the presence of a respiratory copathogen and they should, therefore, utilize as an impulse to initiate a comprehensive diagnostic workout with sampling, rather than as an indicator of an underlying superinfection. 5 The consequence is that empirical antimicrobial therapy is systematically initiated until microbiological documentation of coinfecting pathogens is available. A meta-analysis of studies, reporting antimicrobial prescribing in SARS-CoV-2 infected patients, demonstrated a wide use of broad-spectrum antibacterials in more than 70% of the COVID-19 cases, despite a paucity of evidence for bacterial coinfection, and no antimicrobial stewardship interventions were described. 6 As controversial reports appeared in the literature, the factor timing gained importance, regarding the clinical relevance of laboratory-confirmed coinfecting pathogens in COVID-19 patients and the implication of therapeutic measurements. 7 Some authors reported early-onset coinfections in SARS-CoV-2-infected patients, 8, 9 while others identified late-onset infections. 10 According to the US Centers for Disease Control and Prevention (CDC), a superinfection is "an infection following a previous infection especially when caused by microorganisms that are resistant or have become resistant to the antibiotics used earlier," while a coinfection is one occurring concurrently with the initial infection, the difference being purely temporal. 12 These are the definitions that will be used in the current manuscript.

We present the prevalence and consequences of respiratory coinfections in a consecutive cohort of patients receiving invasive ventilation in Germany's largest department of intensive care medicine between March 2020 and November 2020. 

The respiratory samples were selected either as routine aspirates during a closed endotracheal suction, according to the standards of the clinic, or as bronchoalveolar lavage (BAL) during a bronchoscopy.

Because of the high transmission risk of the COVID-19 infection, a bronchoscopy was only conducted when the following criteria were fulfilled: 1. appearance of a relevant clinical deterioration with amelioration of the respiratory insufficiency and/or pneumogenic sepsis and 2. newly emerged infiltrates in the radiological examination of the chest (conventional radiology and/or computed tomography).

All respiratory samples were processed according to internal standards to allow the detection of conventional bacteria and slowgrowing pathogens, such as mycobacteria and fungi. All samples underwent galactomannan test for the detection of mold infections.

In addition, the diagnostic panel included a multiplex nested PCR assay that could simultaneously detect different respiratory pathogens: 

Sixty-eight (66.7%) of the total 102 patients were male and 34 (33.3%) were female, with a median age of 62.9 years. The median body mass index was 28.2 (range 17.5-44.5). The main pre-existing comorbidities, except overweight and obesity, were respiratory diseases (n = 29), diabetes mellitus (n = 37), and underlying immunosuppression (n = 32). The most prevalent respiratory comorbidities were active cigarette smoking, chronic obstructive pulmonary disease (COPD), bronchial asthma, and obstructive sleep apnea/obesity hypoventilation syndrome (Table 1) . Of the patients with diabetes mellitus, noninsulin-dependent diabetes mellitus type 2 was the most prevalent group (n = 19), followed by insulin-dependent diabetes mellitus type 2 (n = 12), undiagnosed diabetes mellitus (n = 5), and diabetes mellitus type 1 (n = 1). Underlying immunosuppressive conditions were chronic therapy with immunosuppressive drugs (corticosteroids, methotrexate, and lymphodepleting therapeutics) (n = 7), acute myeloid or lymphatic leukemia (n = 9), lymphoma (n = 4), active neoplasia of solid organs The high prevalence of Staphylococcus aureus, described elsewhere as the main pathogen identified in early-onset bacterial coinfection, 8, 9 was not confirmed in our study. Staphylococcus aureus is considered to be a community-acquired coexisting pathogen. According to the CDC definition, infections identified 48 h after hospital admission should be referred to as hospital-acquired and those within 48 h as community-acquired. 12 As the great majority of the ICU patients included in our study was admitted to the hospital several days before their admission to the ICU, no community-acquired infections were expected in this collective.

The evidence of A. fumigatus was present in more than 15% of the overall positive samples. The prevalence of Herpesviridae was even higher, reaching more than 35% of the positive samples, with a predominance of HSV, followed by CMV. We observed a high coincidence between A. fumigatus and HSV infection (5 out of 12

A. fumigatus samples were also positive to HSV). No respiratory viruses or intracellular bacteria could be detected in our cohort. Due to inconsistent definitions and diagnostic criteria of invasive aspergillosis in non-neutropenic critically ill patients, the actual prevalence of this entity in our study population is yet unclear. 17, 18 The inclusion of BAL fluid galactomannan as an additional entry criterion may increase the diagnostic sensitivity for invasive aspergillosis in ICU patients. 19 The coincidence of A. fumigatus with reactivated

Herpesviridae is probably a manifestation of an inadequate local and systemic immune response, rather than an active superinfection, requiring a targeted antimicrobial treatment.

A limitation of our study could be the high percentage of patients, who already received broad-spectrum antibiotics on their admission to the ICU. More than 94% were under an empirical antibiotic therapy before the initiation of the mechanical ventilation and 34% were treated with steroids. This could have influenced the microbiological consistency of the bronchial aspirates.

A comparative study, after the adjustment of the guidelines, 20 

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Maria Paparoupa http://orcid.org/0000-0003-1713-6759

Multiorgan and renal tropism of SARS-CoV-2

Hepatic vasculopathy and regenerative responses of the liver in fatal cases of COVID-19

Severe liver dysfunction complicating course of COVID-19 in the critically ill: multifactorial cause or direct viral effect?

The microbial coinfection in COVID-19

Co-infections in COVID-19 critically ill and antibiotic management: a prospective cohort analysis

Bacterial and fungal coinfection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing

Bacterial and fungal superinfections in critically ill patients with COVID-19

Co-infection with respiratory pathogens among COVID-2019 cases

Bacterial coinfection in critically ill COVID-19 patients with severe pneumonia

Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting

Bacterial pneumonia in COVID-19 critically ill patients: a case series

The role of co-infections and secondary infections in patients with COVID-19. Pneumonia (Nathan)

Rapid multiplex nested PCR for detection of respiratory viruses

Co-infections in people with COVID-19: a systematic review and meta-analysis

Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies

Bacterial and fungal infections among patients with SARS-CoV-2 pneumonia

Performance of existing definitions and tests for the diagnosis of invasive aspergillosis in critically ill, adult patients: a systematic review with qualitative evidence synthesis

Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium

Does galactomannan testing increase diagnostic accuracy for IPA in the ICU? A prospective observational study

Empfehlungen zur intensivmedizinischen Therapie von Patienten mit COVID-19